Minerva Neurosciences, Inc. Increase (Decrease) in Deferred Revenue
Minerva Neurosciences, Inc. (NERV) reported Increase (Decrease) in Deferred Revenue of -$41.18 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-03-01
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-12-31 was $0.00.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-09-30 was $0.00.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was $0.00.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $37.08M.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for fiscal 2020 was -$41.18M.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for fiscal 2017 was $41.18M, a 1516.03% increase from fiscal 2016.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $2.55M.
- Minerva Neurosciences, Inc. increase (decrease) in deferred revenue for fiscal 2015 was -$1.22M, a 200.00% decline from fiscal 2014.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | -$41.18M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$41.18M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | -$41.18M 10-Q · filed 2021-08-02 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $37.08M derived: sum of 2 quarters · filed 2018-03-12 | $40.65M derived: sum of 3 quarters · filed 2018-03-12 | $41.18M 10-K · filed 2018-03-12 |
| 2017-09-30 | $37.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $40.65M derived: sum of 2 quarters · filed 2017-11-06 | $41.18M 10-Q · filed 2017-11-06 | $40.19M derived: sum of 4 quarters · filed 2017-11-06 |
| 2017-06-30 | $3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $4.10M 10-Q · filed 2017-08-03 | $3.11M derived: sum of 3 quarters · filed 2017-08-03 | |
| 2017-03-31 | $530.30K 10-Q · filed 2017-05-04 | -$455.54K derived: sum of 2 quarters · filed 2017-05-04 | ||
| 2016-12-31 | -$985.84K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $2.55M 10-K · filed 2017-03-13 | ||
| 2016-09-30 | $3.53M 10-Q · filed 2016-11-03 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$1.22M 10-K · filed 2017-03-13 | ||
| 2015-09-30 | -$1.22M 10-Q · filed 2016-11-03 | |||
| 2014-12-31 | $1.22M 10-K · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |